A Phase II Study of Ado-Trastuzumab Emtansine in Patients with Cancers Driven by HER2


Full Title

A Phase 2 Trial of Ado-Trastuzumab Emtansine for Patients with HER2 Amplified or Mutant Cancers


Ado-trastuzumab emtansine is used to treat breast cancers that contain too much of an abnormal HER2 protein. The drug binds to HER2 on cancer cell surfaces, and the emtansine breaks off and kills the cancer cell.

In this study, researchers are examining the safety and effectiveness of using ado-trastuzumab emtansine in patients with other cancers fueled by abnormal HER2, including lung, endometrial, colorectal, and bladder cancers. Ado-trastuzumab emtansine is given intravenously (by vein).

Who Can Join

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have lung, colorectal, endometrial, bladder, or other cancers whose growth is driven by HER2.
  • Patients may have had prior treatment (except for ado-trastuzumab emtansine) and must recover from any side effects before entering the study
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Bob Li at 646-888-4201.




Phase II (phase 2)



ClinicalTrials.gov ID